These agents are likely to become the mainstay of cancer treatment in the very near future.
Experts in the management of SARS-CoV-2 educate on CDC and FDA recommendations for approaching administration of booster vaccines, including those for special patient populations.
Utilization of the RAPID3 tool can be a beneficial way for pharmacists to complete disease activity assessments without physically seeing the patient in a clinic setting.
CGM enhances diabetes management in pregnancy, improving outcomes.
Pharmacists play a vital role in therapy selection.
Advanced analytics will continue to make health care more accessible and empower pharmacists with the ability to personalize treatments.
Although it is critical that we listen to every patient we treat, it's also important to listen to the needs of our bodies first, as this will allow us to better care for others.
Vusolimogene oderparepvec in combination with nivolumab is being assessed to treat individuals with unresectable or metastatic stage IIIb-IV cutaneous melanoma.
For COVID-19 to turn into an endemic, there are a few criteria that must be met.
Despite the surge in new diabetes cases, the treatment options in in children remain limited.
As practices have gained experience in the post-COVID-19 environment, health care professionals have found innovative ways to work around many of the obstacles the pandemic presents.
The need for pharmacists to return to a more clinically-focused role became apparent as the COVID-19 pandemic revealed gaps in patient access to care across the country.
Launching development of SOPs and communication with wholesalers is key.
With the introduction of expensive drugs and associated challenges for hospital budgets, pharmacy leaders benefit from strategically managing financial, clinical, and regulatory factors for sustainable care delivery.
Amendments reflecting more contemporary options could raise ethical questions for health care workers.
Patients with type 2 diabetes receiving once-weekly insulin icodec were more likely to reach a hemoglobin A1C level below 7% compared to those who received once-daily insulin analogues.
The program develops patient-centered oncology pharmacists through comprehensive training.